{'fraction_non_alphanumeric': 0.07242582897033159, 'fraction_numerical': 0.041884816753926704, 'mean_word_length': 4.567961165048544, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of endothelial dysfunction on the pathogenesis of urolithiasis in patients with metabolic syndrome

Abstract Objective The aim of the present prospective clinical study was to investigate the possible effect of endothelial dysfunction in urolithiasis. Methods The study included 92 patients older than 18 years. The patients were divided into 4 groups with 23 patients each as group 1: metabolic sydrome (MetS) (−) stone disease (SD) (−), group 2: MetS (−) SD (+), group 3: MetS (+) SD (−) and group 4: MetS (+) SD (+). C-reactive protein, homocysteine, uric acid, and creatinine levels were evaluated between the groups. Endothelial (dys)function was evaluated based on the brachial artery flow-mediated dilation (FMD) measurement. Results The mean age was 41.9 ± 10.2 (range, 18–62) years. Mean FMD value was 15.9 ± 18.2% (range, 24.0–68.5%). A strong significant difference was found between group 1 and 2 (p < .001); group 1 and 3 (p < .001) and group 1 and 4 (p < .001) with regard to FMD. Conclusion These results suggest that endothelial dysfunction plays an important role in the pathogenesis of urolithiasis in patients with MetS.